Morphic Therapeutic and J&J division Janssen Biotech entered into a collaborative deal to develop novel integrin therapeutics for conditions not adequately addressed by current therapies.
Morphic Therapeutic Announces $80 Million Financing to Advance Next-Generation Oral Integrin Therapeutics Through Clinical Proof of Concept
Autoimmune Diseases, Biology, Biotech, Business, Drug Discovery, Fibrosis, Financing, Human Cells, Immuno-oncology, Integrins, Preclinical Data, Series B Preferred StockMorphic Therapeutic has completed a $80 million Series B financing to fund the biotechnology company’s two lead programs through clinical proof of concept, and to advance multiple other programs into the clinic.